{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:28Z","timestamp":1788335068939,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006512","name":"School of Medicine, Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ebiom.2025.106096","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T10:19:33Z","timestamp":1767349173000},"page":"106096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease"],"prefix":"10.1016","volume":"123","author":[{"given":"Neha","family":"Regmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Abar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4373-4800","authenticated-orcid":false,"given":"Jeong-A","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kenney-Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Malinzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Hagarty-Waite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-8992","authenticated-orcid":false,"given":"Karra A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hye","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlee R.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-909X","authenticated-orcid":false,"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.106096_bib1","series-title":"Glycogen Storage Disease Type II, Acid \u03b1-Glucosidase (Acid Maltase) Deficiency","first-page":"3389","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ebiom.2025.106096_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J Pediatr"},{"key":"10.1016\/j.ebiom.2025.106096_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.ebiom.2025.106096_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid \u03b1-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.ebiom.2025.106096_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2025.106096_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.ebiom.2025.106096_bib7","first-page":"412","article-title":"Nervous system in Pompe's disease. Ultrastructure and biochemistry. J. Neuropathol","volume":"30","author":"Gambetti","year":"1971","journal-title":"Exp Neurol"},{"key":"10.1016\/j.ebiom.2025.106096_bib8","series-title":"Springer Berlin Heidelberg","first-page":"45","author":"Pena","year":"2015"},{"key":"10.1016\/j.ebiom.2025.106096_bib9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.ebiom.2025.106096_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ebiom.2025.106096_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ebiom.2025.106096_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108119","article-title":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"141","author":"Kenney-Jung","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ebiom.2025.106096_bib13","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1212\/WNL.0000000000207482","article-title":"Neurofilament light and its association with CNS involvement in patients with classic infantile Pompe disease","volume":"101","author":"Mackenbach","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2025.106096_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jimd.12736","article-title":"Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning","volume":"47","author":"van den Dorpel","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ebiom.2025.106096_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170199","article-title":"AAV-mediated delivery of secreted acid \u03b1-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice","volume":"8","author":"Meena","year":"2023","journal-title":"JCI insight"},{"key":"10.1016\/j.ebiom.2025.106096_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous injection of an AAV-PHP.B vector encoding human acid \u03b1-glucosidase rescues both muscle and CNS defects in murine Pompe disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ebiom.2025.106096_bib17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/acn3.51449","article-title":"Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children","volume":"8","author":"Nitz","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ebiom.2025.106096_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/brain\/awab304","article-title":"Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy","volume":"145","author":"Beerepoot","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.ebiom.2025.106096_bib19","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1007\/s00415-024-12679-5","article-title":"Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain\u2013Barr\u00e9 syndrome","volume":"271","author":"Hafsteinsd\u00f3ttir","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.ebiom.2025.106096_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gim.2022.10.005","article-title":"Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease","volume":"25","author":"Hsu","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.ebiom.2025.106096_bib21","series-title":"Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset Pompe?JIMD Reports","first-page":"55","author":"Broomfield","year":"2017"},{"key":"10.1016\/j.ebiom.2025.106096_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1523\/JNEUROSCI.3742-14.2015","article-title":"Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system","volume":"35","author":"Plog","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.ebiom.2025.106096_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2025.106096_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.brainres.2014.12.027","article-title":"Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease","volume":"1600","author":"Petzold","year":"2015","journal-title":"Brain Res"},{"key":"10.1016\/j.ebiom.2025.106096_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ebiom.2025.106096_bib26","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1212\/WNL.0000000000009979","article-title":"Novel approaches to quantify CNS involvement in children with Pompe disease","volume":"95","author":"Korlimarla","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2025.106096_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101590","article-title":"Infantile-onset Pompe disease entering adulthood: insights from two decades of enzyme replacement therapy experience - PubMed","volume":"27","author":"Regmi","year":"2025","journal-title":"Genet Med"},{"key":"10.1016\/j.ebiom.2025.106096_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2017.04.014","article-title":"Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up","volume":"121","author":"Spiridigliozzi","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ebiom.2025.106096_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/WNL.57.5.906","article-title":"Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2","volume":"57","author":"Martini","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2025.106096_bib30","first-page":"379","article-title":"Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings","volume":"27","author":"Teng","year":"2004","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.ebiom.2025.106096_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jnnp.26.5.422","article-title":"Neuropathological and neurochemical aspects of generalized glycogen storage disease","volume":"26","author":"Crome","year":"1963","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ebiom.2025.106096_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.12659\/AJCR.893309","article-title":"Small-fiber neuropathy in Pompe disease: first reported cases and prospective screening of a clinic cohort","volume":"16","author":"Hobson-Webb","year":"2015","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ebiom.2025.106096_bib33","first-page":"968","article-title":"Late-onset Pompe disease associated with polyneuropathy. Neuromuscul","volume":"29","author":"Lamartine","year":"2019","journal-title":"Disord"},{"key":"10.1016\/j.ebiom.2025.106096_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.01054","article-title":"Comparing Glial fibrillary acidic protein (GFAP) in serum and plasma following mild traumatic brain injury in older adults","volume":"11","author":"Huebschmann","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.ebiom.2025.106096_bib35","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.2147\/JIR.S342097","article-title":"Glial fibrillary acidic protein (GFAP): neuroinflammation biomarker in acute ischemic stroke","volume":"14","author":"Amalia","year":"2021","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.ebiom.2025.106096_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03120-1","article-title":"Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study","volume":"21","author":"Lin","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.ebiom.2025.106096_bib37","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/s41380-025-02939-9","article-title":"Neuroinflammatory fluid biomarkers in patients with Alzheimer's disease: a systematic literature review","volume":"30","author":"Heneka","year":"2025","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.ebiom.2025.106096_bib38","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.12998\/wjcc.v11.i15.3385","article-title":"Astrocytes in the central nervous system and their functions in health and disease: a review","volume":"11","author":"Gradisnik","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ebiom.2025.106096_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35766-w","article-title":"Levels of plasma neurofilament light chain and cognitive function in patients with alzheimer or Parkinson disease","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425005468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425005468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:19:08Z","timestamp":1773962348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425005468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S2352396425005468"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106096","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106096"}}